已收盤 08-01 16:00:00 美东时间
-0.010
-0.23%
Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $15 price target.
08-01 23:08
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
The latest update is out from COMPASS Pathways ( ($CMPS) ). On July 28, 2025, C...
07-29 18:58
Compass Pathways Plc (($CMPS)) announced an update on their ongoing clinical st...
07-25 00:21
https://www.washingtonpost.com/health/2025/07/16/psychedelics-rfk-jr-kennedy-ibogaine-mdma/41658b06-6246-11f0-bf70-56d8888ebb94_story.html
07-16 23:03
HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $45 price target.
07-15 23:06
https://www.bloomberg.com/news/articles/2025-06-30/colorado-moves-to-allow-hallucinogen-ibogaine-for-medical-use?embedded-checkout=true
06-30 23:58
https://www.marijuanamoment.net/house-votes-to-let-va-doctors-recommend-medical-marijuana-to-military-veterans-and-to-support-psychedelics-research/
06-26 01:42
多家机构首予Amrize买入评级,目标价53~62美元;HC Wainwright & Co.上调内克塔治疗目标价至120美元,维持"买入"评级>>
06-25 08:39